Pharmacogenomics and active surveillance for serious adverse drug reactions in children

Tenneille T. Loo, Colin J.D. Ross, Johanna Sistonen, Henk Visscher, Parvaz Madadi, Gideon Koren, Michael R. Hayden, Bruce C. Carleton

نتاج البحث: نشر في مجلةمقالة مرجعية مراجعة النظراء

18 اقتباسات (Scopus)

ملخص

Juxtaposing clinical pharmacology with human genetics, pharmacogenomics utilizes a patients genetic information to identify genetic variants that have the potential to provide clinically relevant predictions of toxicity and efficacy. The goal is to develop personalized and genetic-based predictions of an individuals drug response and likelihood of experiencing an adverse drug reaction. The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) has implemented active adverse drug reaction surveillance to monitor and discover genetic markers related to serious adverse drug reactions in the pediatric population. Evidence-based pharmacogenomics research will inform public policy and influence drug benefit-risk decision-making. Regulatory processes and future challenges in pharmacogenomics research will be discussed.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)1269-1285
عدد الصفحات17
دوريةPharmacogenomics
مستوى الصوت11
رقم الإصدار9
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - سبتمبر 2010
منشور خارجيًانعم

بصمة

أدرس بدقة موضوعات البحث “Pharmacogenomics and active surveillance for serious adverse drug reactions in children'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا